SCHEMBL18675554

SCHEMBL18675554

N#CCC(=O)NC1(c2ccccc2)CCCC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.62
SSTR4 P31391 1/20 0.47
MCL1 Q07820 1/20 0.46
DPP4 P27487 2/20 0.45
CTSL P07711 1/20 0.43
CTSK P43235 1/20 0.42
TACR3 P29371 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
AKR1C1 Q04828 1/20 0.41
POLB P06746 1/20 0.41
HDAC4 P56524 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
DPP7 Q9UHL4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17320670 0.85 HSD17B10 (0.46) HSD17B10SSTR4MCL1CTSLCTSK
SCHEMBL18675568 0.84 HSD17B10 (0.45) HSD17B10SSTR4MCL1DPP4CTSL
SCHEMBL18681903 0.84 HSD17B10 (0.48) HSD17B10CTSLCTSKCTSBCTSS
SCHEMBL17321816 0.79 IDO1 (0.47) HSD17B10CTSLCTSKCTSBCTSS
SCHEMBL14263840 0.78 SSTR4 (0.52) SSTR4DPP4TACR3AKR1C1POLB
SCHEMBL3560390 0.77 SSTR4 (0.56) HSD17B10SSTR4TACR3AKR1C1POLB
SCHEMBL23343877 0.76 POLB (0.50) SSTR4DPP4TACR3AKR1C1POLB
SCHEMBL28606841 0.76 SSTR4 (0.50) SSTR4DPP4TACR3AKR1C1POLB
SCHEMBL17320671 0.75 HSD17B10 (0.38) HSD17B10MCL1DPP4POLBALDH1A1
SCHEMBL17321362 0.75 NPSR1 (0.47) HSD17B10CTSLCTSBCTSSPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170088520-A1 DEUBIQUITINASE INHIBITORS PHARMAKEA, INC. 2017-03-30 US disclosed
US-20170088520-A1 DEUBIQUITINASE INHIBITORS PHARMAKEA, INC. 2017-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088520-A1 DEUBIQUITINASE INHIBITORS USP30, USP1, USP28 HSD17B10 2097/4885SSTR4 4514/4885MCL1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.